Propanc Biopharma Inc PPCB

$1.78 +0.05 (2.89%)

Valuation

Market cap
1,127,000
Revenue TTM
$0
Net income TTM
$-18,860,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.05

Trading

Volume
27,800
Avg volume
32,265
Day's range
$1.74 – $2.00
Shares out
633,000
Stochastic %K
44%
Beta
3.55
Analysts
—
Price target
$12.50

Price

Company profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a resea...

Show more

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9882 0780
Website
https://www.propanc.com
Address
302, 6 Butler Street, Camberwell, Australia

Latest news

Stocktwits

URANIUM77 Nov 20, 3:36 PM
$PPCB Amazing loading up zone now
0 replies
GridironGainz Nov 19, 9:07 PM 0 replies
IR_propancbiopharma Nov 19, 1:48 PM
From preclinical research to clinical development preparations, several milestones have helped shape $PPCB's path forward in 2026. · Q1: Preclinical findings, research collaborations, and bioanalytical development. · Q2: GMP manufacturing preparations to support clinical development. · Q3: Clinical protocol development, site feasibility assessments, and a clearer Phase 1b roadmap. · Q4: Additional preclinical findings, analytical progress, and preparations for regulatory and ethics submissions. What's next? Propanc is targeting a Phase 1b first-in-human study involving up to 50 patients with advanced solid tumors, with initial patient screening planned for February 2027. The next milestone is translating these preparations into clinical execution.
0 replies
URANIUM77 Nov 19, 12:31 PM
$PPCB Propanc Biopharma ($PPCB) results show 90% inhibition of tumor growth. FDA Orphan Drug Designation for pancreatic cancer—and more is on the way. An amazing journey lies ahead.
0 replies
Maxandbear Nov 18, 10:54 PM
$PPCB I have held this so long I forgot I had the shares.
0 replies
Maxandbear Nov 18, 10:53 PM
$PPCB that is it.
0 replies
Maxandbear Nov 18, 10:53 PM
$PPCB there is one egg that posts.
0 replies
Maxandbear Nov 18, 10:52 PM
$PPCB I am still down $800 just gibberish on this company.
0 replies